Your browser doesn't support javascript.
loading
How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.
Fuji, S; Rovó, A; Ohashi, K; Griffith, M; Einsele, H; Kapp, M; Mohty, M; Majhail, N S; Engelhardt, B G; Tichelli, A; Savani, B N.
Afiliação
  • Fuji S; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
  • Rovó A; Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.
  • Ohashi K; Department of Hematology, University Hospital of Bern, Bern, Switzerland.
  • Griffith M; Department of General Medicine, National Cancer Center Hospital, Tokyo, Japan.
  • Einsele H; Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Kapp M; Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.
  • Mohty M; Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.
  • Majhail NS; Department of Haematology, Saint Antoine Hospital, Paris, France.
  • Engelhardt BG; Blood and Marrow Transplant Program, Cleveland Clinic, Cleveland, OH, USA.
  • Tichelli A; Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.
  • Savani BN; Department of Internal Medicine, Division of Hematology, University Hospital Basel, Basel, Switzerland.
Bone Marrow Transplant ; 51(8): 1041-9, 2016 Aug.
Article em En | MEDLINE | ID: mdl-27042848
ABSTRACT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients frequently develop glucose intolerance and post-transplant diabetes mellitus (PTDM). The clinical importance of PTDM and its detrimental impact on HSCT outcomes are under-recognized. After allo-HSCT, various mechanisms can contribute to the development of PTDM. Here we review information about hyperglycemia and PTDM after allo-HSCT as well as PTDM after solid organ transplantation and describe ways to manage hyperglycemia/PTDM after allogeneic HSCT. Taking into consideration a lack of well-established evidence in the field of allo-HSCT, more studies should be conducted in the future, which will require closer multidisciplinary collaboration between hematologists, endocrinologists and nutritionists.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Diabetes Mellitus / Hiperglicemia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Diabetes Mellitus / Hiperglicemia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Bone Marrow Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Japão